Ingersoll Rand Inc. (IR) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows mixed signals: stable financial performance with unchanged revenue guidance, but reduced EPS guidance and tariff impacts. Positive aspects include innovation in product launches and strong recurring revenue growth. The Q&A reflects cautious optimism with stable market trajectories and positive indicators, but no significant recovery expected. The lack of detailed guidance and tariff impacts weigh on sentiment. Overall, the balance of positive and negative factors suggests a neutral stock price movement.
Key Financial Performance
Organic Order Growth Low single-digit organic order growth for both the fourth quarter and the full year. Reasons: Positive momentum heading into 2026.
Recurring Revenue Exceeded $450 million in 2025, with a backlog of approximately $1.1 billion in future revenue from existing contracts. Reasons: Progress towards recurring revenue targets.
Inorganic Revenue Generated approximately $275 million in annualized inorganic revenue from $525 million invested across 16 transactions. Reasons: High-return acquisitions and expanded technological capabilities.
Orders Up 8% year-over-year in Q4, or 1% organically. Reasons: Strength in ITS and PST segments.
Revenue Up 10% year-over-year in Q4. Organic revenue grew 3% year-over-year. Reasons: Positive price and volume.
Adjusted EBITDA (Q4) $580 million with margins at 27.7%. Reasons: Durability of operating model, margin pressure from tariff impacts, and commercial investments for growth.
Adjusted Earnings Per Share (Q4) $0.96, up 14% year-over-year. Reasons: Strong financial performance.
Total Revenue (Full Year) Up 6% year-over-year. Organic revenue down 1%. Reasons: Tough first half comps, improvement in trajectory as the year progressed.
Adjusted EBITDA (Full Year) Approximately $2.1 billion with a margin of 27.4%. Reasons: Strong execution and financial performance.
Adjusted Earnings Per Share (Full Year) $3.34, up 2% year-over-year. Reasons: Strong financial performance.
Free Cash Flow (Q4) $462 million. Reasons: Strong liquidity and balance sheet flexibility.
ITS Segment Revenue Grew 11% year-over-year, including organic revenue growth of 3%. Reasons: Positive organic order growth in all regions.
ITS Adjusted EBITDA Margins 28.9%, down year-over-year. Reasons: Tariff impacts and commercial investments for growth.
PST Segment Revenue Up 8% year-over-year in Q4, with organic revenue growth of 4%. Reasons: Strong execution and mid-teens organic order growth in Life Science businesses.
PST Adjusted EBITDA Margins 30.4%, up 280 basis points year-over-year. Reasons: Strong execution and relatively easy comp from Q4 of prior year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Recurring Revenue Initiative: Exceeded $450 million in 2025, with a backlog of approximately $1.1 billion in future revenue from existing contracts.
Scinomix Acquisition: Acquired Scinomix, a manufacturer specializing in workflow optimization technologies for life sciences, advancing the Life Science strategy.
Aeration Technology for Wastewater: Introduced advanced aeration technology integrated with high-efficiency blowers, achieving up to 34% energy savings.
EZ JetFlo Product: Launched a disposable single-use mixer for biopharma production, improving safety, reducing cross-contamination, and enhancing operational efficiency.
Geographic Expansion: Positive organic order growth in Americas, EMEA, and Asia Pacific regions, with notable growth in China and the rest of Asia.
M&A Investments: Invested $525 million across 16 transactions in 2025, generating $275 million in annualized inorganic revenue.
Operational Efficiency: Achieved adjusted EBITDA margins of 27.7% in Q4 and 27.4% for the full year, despite tariff impacts and commercial investments.
Capital Deployment: Deployed $1 billion in share repurchases, $32 million in dividends, and maintained leverage under 2x.
Guidance for 2026: Projected revenue growth of 2.5%-4.5%, adjusted EBITDA of $2.13-$2.19 billion, and adjusted EPS growth of approximately 5%.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff Impacts: Year-over-year margin pressure was primarily driven by tariff impacts, which could continue to affect profitability.
Commercial Investments: Intentional commercial investments for growth have led to margin pressure, indicating a potential challenge in balancing growth and profitability.
Challenging Market in China: Despite growth, the market in China remains challenging, which could impact future performance in the region.
Regulatory and Safety Standards: Products like EZ JetFlo are designed to meet stringent safety and regulatory standards, which could pose challenges in maintaining compliance and innovation.
Economic Uncertainty: The company emphasizes agility and readiness to adapt to ongoing changes in the global market landscape, indicating potential risks from economic uncertainties.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Total company revenue is expected to grow between 2.5% and 4.5% in 2026, driven by organic order growth of 1% at the midpoint, 1.5% growth from M&A, and 1% FX tailwind.
Adjusted EBITDA: Expected to be in the range of $2.13 billion to $2.19 billion for 2026.
Adjusted EPS: Projected to fall within the range of $3.45 to $3.57, representing approximately 5% growth at the midpoint.
Adjusted Tax Rate: Anticipated to be approximately 23% for 2026.
Net Interest Expense: Expected to be about $230 million in 2026.
Share Count: Projected to be approximately 394 million in 2026.
Free Cash Flow Conversion: Expected to be around 95% of adjusted net income.
Revenue Phasing: Revenue, adjusted EBITDA, and adjusted EPS phasing is expected to be consistent with prior years, with mid-single-digit EPS growth in both the first and second half of 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends paid in 2025: $32 million
Share repurchases in 2025: $1 billion
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What sort of end market trajectory is embedded in the guidance, and are there any signs of change in shorter cycle businesses?
A:The guidance assumes a stable trajectory with no market recovery embedded. The portfolio demonstrates resiliency, with 40% of revenue from stable aftermarket. Life Sciences is improving sequentially, with strong funnel and booking activity in pharma and biopharma production. General industrial markets show stability, and long-cycle projects have a healthy funnel. PMI serves as a leading indicator for short-cycle businesses, but management is cautious about calling a meaningful inflection based on one data point.
Q:Are there any end markets that management is specifically worried about this year?
A:Management is not embedding any market recovery in the guidance and sees stability. Headwinds from RNG, electric vehicle, and photovoltaic markets are largely behind. The China market has shown positive organic order growth for three consecutive quarters, driven by innovation and new solutions.
Q:What is the seasonality expectation for organic revenue and EPS growth in 2026?
A:Organic revenue growth is expected to be flat to slightly down in Q1, with low single-digit growth in Q2, Q3, and Q4. EPS growth is expected to be mid-single digits year-on-year in both halves, with relatively even earnings growth on a quarterly basis.
Q:What is the margin profile expectation for 2026, and how are price/cost dynamics expected to play out?
A:Full-year EBITDA margins are expected to be flattish. Margins may decline slightly in the first half due to tariff impacts but are expected to improve in the second half due to pricing actions, productivity measures, and internal cost controls. Price/cost is expected to be neutral in the first half and positive for the full year.
Q:Are there any signs of pickup in short-cycle businesses, and does the guidance anticipate positive volume growth in the back half of the year?
A:There are signs of pickup in short-cycle businesses, with order momentum continuing into January. However, the guidance does not assume meaningful recovery, and volume performance is expected to improve in the second half, likely reaching flattish levels by year-end.
Q:What is included in the guidance regarding capital deployment?
A:The guidance includes the annualization of $1 billion in share repurchases from 2025, carryover impacts of 2025 acquisitions, and the Scinomix acquisition in 2026. Interest expense is expected to remain consistent with 2025 levels.
Q:What is the composition of the acquisition pipeline, and are there any larger deals expected?
A:The acquisition pipeline is strong, with 9 companies under LOI. Most opportunities are bolt-on in nature, but there are a few larger deals, potentially around $1 billion, being cultivated.
Q:What is driving the growth in recurring revenue, and what is the outlook for 2026?
A:Recurring revenue has grown from $200 million to over $450 million in recent years, with $1.1 billion in future revenue from existing contracts. Growth is driven by regional and technological expansion, and the ramp is expected to continue, though not linearly.
Q:What is the outlook for Life Sciences and longer cycle projects in 2026?
A:Life Sciences is expected to perform well, with strong order momentum in pharma, biopharma, and medical devices. Longer cycle projects have a healthy funnel, though decision-making remains elongated. Projects are not being canceled, and the funnel continues to grow.
Q:What are the expectations for cost actions and productivity gains in 2026?
A:The guidance includes savings from restructuring actions taken in 2025, normal course productivity improvements, and targeted pricing actions. These measures are expected to offset tariff-related headwinds and support margin improvement in the second half.
Q:What are the forward-looking indicators for the business, and what do they suggest?
A:PMI and marketing qualified leads (MQLs) are key indicators. PMI recently turned positive in the U.S., and MQLs show good momentum, particularly from new customer accounts. These indicators suggest improving trends, though decision-making remains elongated.
Q:What is the margin profile of the recurring revenue business?
A:The recurring revenue business has a higher margin profile, typically above 60% gross margin. However, ongoing reinvestments in service technicians and commercial growth are moderating the margin expansion in the near term.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the scale of price/cost headwinds in dollars or margin percentage, and the exact margin profile of acquisitions expected in 2026 was not disclosed. Additionally, while they mentioned positive trends in China and Life Sciences, they did not provide detailed numerical guidance for these segments.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
IRX engine
Ingersoll Rand
LOI acquisition
Orders book
PST segment
Relations statement
Science technology
Slide Orders
Slide flywheel
Slide note
accuracy traceability
acquisition Life
acquisition manufacturer
acquisition multiple
backlog contract
bill PST
bill price
book bill
capital share
comp improvement
contract demonstration
core engine
deal value
demonstration progress
deployment efficiency
dividend ability
durability model
efficiency precision
end laboratory
engine market
flexibility segment
flow return
flywheel core
flywheel deal
focus portfolio
impact investment
improvement trajectory
momentum
segment digit
IR Transcript
Ingersoll Rand Inc. (IR) Presents at Citi's Global Industrial Tech & Mobility Conference 2026 Transcript
Neutral2-19
Ingersoll Rand Inc. (IR) Presents at Barclays 43rd Annual Industrial Select Conference Transcript
Neutral2-18
Ingersoll Rand Inc. (IR) Q4 2025 Earnings Call Transcript
Unknown2-13
The earnings call summary shows mixed signals: stable financial performance with unchanged revenue guidance, but reduced EPS guidance and tariff impacts. Positive aspects include innovation in product launches and strong recurring revenue growth. The Q&A reflects cautious optimism with stable market trajectories and positive indicators, but no significant recovery expected. The lack of detailed guidance and tariff impacts weigh on sentiment. Overall, the balance of positive and negative factors suggests a neutral stock price movement.
Ingersoll Rand Inc. (IR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
IR Slides
IR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
